IN THE CLAIMS:

Claims 1-11, 13, 16, and 20-21, were previously cancelled. Claim 19 has been amended herein. All of the pending claims 12, 14, 15, 17-19, and 22-27 are presented below. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of the Claims:

1-11. (Cancelled).

12. (Previously Presented) A process for producing a cytotoxic T-cell against a minor histocompatibility antigen HA-1, the process comprising:

providing an isolated, synthetic or recombinant peptide having up to fifteen (15) amino acids and comprising the sequence VLXDDLLEA (SEQ ID NO: 1), wherein X represents histidine or arginine;

pulsing an antigen presenting cell with the isolated, synthetic or recombinant peptide; and

co-culturing the antigen presenting cell with an autologous unprimed CD8+ T cell resulting in stimulation of the autologous unprimed CD8+ T cell by the antigen presenting cell, thus producing the cytotoxic T-cell.

13. (Cancelled).

14. (Previously presented) The process according to claim 12, wherein the minor antigen is HA-1.

15. (Previously Presented) The process according to claim 12, wherein co-culturing the antigen presenting cell with an autologous unprimed CD8+ T cell is carried out ex vivo.

16. (Cancelled).

17. (Previously presented) The process according to claim 12, wherein the cytotoxic T-cell is immortalized.

18. (Previously presented) The process according to claim 12, wherein the cytotoxic T-cell is capable of expansion.

19. (Currently Amended) ~~A~~ An isolated VLXDDLLEA (SEQ ID NO: 1) peptide specific cytotoxic T-cell, produced by the process according to claim 12.

20-21. (Cancelled).

22. (Previously presented) The process according to claim 12, wherein the isolated, synthetic or recombinant peptide is flanked by enzymatic cleavage sites.

23. (Previously presented) The process of claim 12 wherein the isolated, synthetic or recombinant peptide consists of SEQ ID NO:2.

24. (Previously presented) The process of claim 12 wherein the isolated, synthetic or recombinant peptide consists of SEQ ID NO:5.

25. (Previously presented) The process according to claim 12, further comprising transducing the cytotoxic T-cell with a gene that codes for herpes simplex virus thymidine kinase.

26. (Previously Presented) A process for producing a cytotoxic T-cell against a minor histocompatibility antigen HA-1, the process comprising:

providing an isolated, synthetic or recombinant peptide consisting of the amino acid sequence of SEQ ID NO:2;

pulsing an antigen presenting cell with the isolated, synthetic or recombinant peptide; and

co-culturing the antigen presenting cell with an autologous unprimed CD8+ T cell resulting in stimulation of the autologous unprimed CD8+ T cell by the antigen presenting cell, thus producing the cytotoxic T-cell against the minor histocompatibility antigen HA-1.

27. (Previously Presented) A process for producing a cytotoxic T-cell against a minor histocompatibility antigen HA-1, the process comprising:

providing an isolated, synthetic or recombinant peptide consisting of the amino acid sequence of SEQ ID NO:5;

pulsing an antigen presenting cell with the isolated, synthetic or recombinant peptide; and

co-culturing the antigen presenting cell with an autologous unprimed CD8+ T cell resulting in stimulation of the autologous unprimed CD8+ T cell by the antigen presenting cell, thus producing the cytotoxic T-cell against the minor histocompatibility antigen HA-1.